HBIO
HARVARD BIOSCIENCE INC
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$8.09
+0.00%Year over year
Reported trailing growth
- Revenue
- -1.1%
- EBITDA
- +96.3%
- EBIT
- +102.0%
- EPS
- +82.1%
- Free cash flow
- —
- Operating cash flow
- -90.2%
Forward estimates
Based on analyst estimates
- Revenue
- +5.5%
- EBITDA
- +775.7%
- EPS
- +127.9%
Three-year CAGR
- Revenue
- -8.6%
- EBITDA
- —
- EBIT
- +89.9%
- Net income
- —
- EPS
- —
- Free cash flow
- -30.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026